1-5 of 5
Masha Fridkis-Hareli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Alonso Ricardo, PhD, Michelle Arata, MS, Steven DeMarco, PhD, Ketki Dhamnaskar, MS, Robert Hammer, PhD, Masha Fridkis-Hareli, PhD, Vaishnavi Rajagopal, PhD, Kathleen Seyb, PhD, Guo-Qing Tang, PhD, Sylvia Tobe, PhD, Douglas Treco, PhD
Journal: Blood
Blood (2015) 126 (23): 939.
https://doi.org/10.1182/blood.V126.23.939.939
Published: 2015
Journal Articles

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization

Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, Michela Sica, Luigi del Vecchio, Christopher J. Horvath, Masha Fridkis-Hareli, Carmine Selleri, Margaret A. Lindorfer, Ronald P. Taylor, Lucio Luzzatto, V. Michael Holers
Journal: Blood
Blood (2012) 119 (26): 6307–6316.
https://doi.org/10.1182/blood-2011-12-398792
Published: 2012
Includes: Supplemental data
Journal Articles

Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases

Masha Fridkis-Hareli, Michael Storek, Istvan Mazsaroff, Antonio M. Risitano, Ante S. Lundberg, Christopher J. Horvath, V. Michael Holers
Journal: Blood
Blood (2011) 118 (17): 4705–4713.
https://doi.org/10.1182/blood-2011-06-359646
Published: 2011
Includes: Supplemental data
Journal Articles

C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes

Antonio M. Risitano, MD, PhD, Caterina Pascariello, Luigi Del Vecchio, MD, Christopher J Horvath, DVM, MS, DACVP, Masha Fridkis-Hareli, PhD, V. Michael Holers, MD, Margaret A Lindorfer, PhD, Ronald P Taylor, PhD
Journal: Blood
Blood (2010) 116 (21): 637.
https://doi.org/10.1182/blood.V116.21.637.637
Published: 2010
Journal Articles

TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis

Masha Fridkis-Hareli, PhD, Michael Storek, PhD, Antonio M. Risitano, MD, PhD, Ante S. Lundberg, MD, Christopher J Horvath, DVM, MS, DACVP, V. Michael Holers, MD
Journal: Blood
Blood (2010) 116 (21): 638.
https://doi.org/10.1182/blood.V116.21.638.638
Published: 2010